Condition: Cervical High Grade Squamous Intraepithelial Lesion · Cervical Intraepithelial Neoplasia Grade 2/3 · CIN 2/3 · Sponsor: Catharina Ziekenhuis Eindhoven
Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish. Complete response to imiquimod occurs in 55-73% of patients, however side-effects of imiquimod are common and can be extensive. Therefore, biomarkers which can predict response to imiquimod therapy are warranted, to increase therapy efficacy and to avoid side effects in patients who will not respond. This prospective, multi-center cohort study aims to validate the potential of immune related biomarkers to predict the clinical response of patients with primary cHSIL to imiquimod, aims to explore the value of these immune biomarkers in recurrent/residual cHSIL to predict treatment responses for imiquimod and aims to explore their potential in spontaneous regression of cHSIL (CIN2).
This description comes directly from the study's public registry record.
Caroline Muntinga, MD · 040 - 239 93 00 · predict-topic@catharinaziekenhuis.nl
Always discuss trial participation with your own doctor first.
| Amphia | Breda, Netherlands | Recruiting |
| Albert Schweitzer Ziekenhuis | Dordrecht, Netherlands | Recruiting |
| Catharina Ziekenhuis Eindhoven | Eindhoven, Netherlands | Recruiting |
| Tergooi MC | Hilversum, Netherlands | Recruiting |
| Medisch Centrum Leeuwarden | Leeuwarden, Netherlands | Recruiting |
| Leiden Universitair Medisch Centrum | Leiden, Netherlands | Not Yet Recruiting |
| Maastricht Universitair Medisch Centrum | Maastricht, Netherlands | Recruiting |
| Radboudumc | Nijmegen, Netherlands | Recruiting |
| Erasmus Medisch Centrum | Rotterdam, Netherlands | Recruiting |
| Franciscus Gasthuis & Vlietland | Rotterdam, Netherlands | Recruiting |
| HagaZiekenhuis | The Hague, Netherlands | Recruiting |
| Diakonessenhuis | Utrecht, Netherlands | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05405270